| Economic analysis of bevacizumab, cetuximab, and panitumumab with fluoropyrimidine-based chemotherapy in the first-line treatment of KRAS wild-type metastatic colorectal cancer … D Lawrence, M Maschio, KJ Leahy, S Yunger, JC Easaw, MC Weinstein Journal of medical economics 16 (12), 1387-1398, 2013 | 51 | 2013 |
| Cost-effectiveness analysis of neoadjuvant pertuzumab and trastuzumab therapy for locally advanced, inflammatory, or early HER2-positive breast cancer in Canada CL Attard, AN Pepper, ST Brown, MF Thompson, PO Thuresson, ... Journal of medical economics 18 (3), 173-188, 2015 | 48 | 2015 |
| Safety profile and costs of related adverse events of trastuzumab emtansine for the treatment of HER2-positive locally advanced or metastatic breast cancer compared to … C Piwko, C Prady, S Yunger, E Pollex, A Moser Clinical drug investigation 35, 487-493, 2015 | 10 | 2015 |
| Economic evaluation of rituximab in addition to standard of care chemotherapy for adult patients with acute lymphoblastic leukemia J Nam, R Milenkovski, S Yunger, M Geirnaert, K Paulson, M Seftel Journal of medical economics 21 (1), 47-59, 2018 | 9 | 2018 |
| PCN143 Cost-effectiveness observations and oncology drug reimbursement recommendations in Canada by the joint oncology drug review CC Ciapanna, S Yunger, D Shum, D Milliken, CJ Longo, F Aissa Value in Health 13 (3), A51, 2010 | 2 | 2010 |
| Safety profile and costs of related adverse events of trastuzumab emtansine compared to other regimens in the Canadian health care system C Piwko, C Prady, S Yunger, A Moser, P Le, C Vicente Value in Health 16 (7), A401, 2013 | 1 | 2013 |
| Canadian Economic Analysis of Bevacizumab, Cetuximab, and Panitumumab in the First Line Treatment of Kras Wild-Type Metastatic Colorectal Cancer (MCRC) D Lawrence, M Maschio, S Yunger, J Easaw, N Aucoin, M Weinstein Annals of Oncology 23, ix202, 2012 | 1 | 2012 |
| Gaps in Access to Patient Care for Patients with Rare Hematological Disorders R Lachance, DA Stewart, K Worthington, B Mistry, S Yunger, JM Garnica, ... Blood 118 (21), 4752, 2011 | 1 | 2011 |
| PHP78 UNDERSTANDING DRUG REIMBURSEMENT RECOMMENDATIONS IN CANADA BY THE COMMON DRUG REVIEW (CDR) EC Siu, S Yunger, F Aissa, D Milliken, D Shum Value in Health 13 (3), A96, 2010 | 1 | 2010 |
| PMS34 AN EXPLORATORY EVALUATION OF THE COST-EFFECTIVENESS OF RITUXIMAB AND ABATACEPT IN THE TREATMENT OF MODERATE TO SEVERE RHEUMATOID ARTHRITIS AFTER AN INADEQUATE RESPONSE TO … S Yunger, B Mistry Value in Health 12 (3), A70, 2009 | 1 | 2009 |
| COST-EFFECTIVENESS OF RITUXIMAB IN ADDITION TO STANDARD OF CARE CHEMOTHERAPY FOR ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA J Nam, M Geirnaert, R Milenkovski, K Paulson, S Yunger, M Seftel HAEMATOLOGICA 102, 296-296, 2017 | | 2017 |
| THE ECONOMIC BURDEN OF ILLNESS OF TREATING ADULT ACUTE LYMPHOBLASTIC LEUKEMIA IN CANADA J Nam, RB Milenkovski, S Yunger, M Geimaert, M Seftel VALUE IN HEALTH 20 (5), A101-A102, 2017 | | 2017 |
| Reimbursement Recommendations Based on Phase II Clinical Evidence for Oncology Drugs in Canada RB Milenkovski, S Yunger, D Shum Value in Health 19 (3), A163, 2016 | | 2016 |
| Abstract P4-12-16: Safety profile and costs of related adverse events of trastuzumab emtansine compared to other regimens in the Canadian health care system C Piwko, S Yunger, A Moser, L Peter, C Vicente Cancer Research 73 (24 Supplement), P4-12-16-P4-12-16, 2013 | | 2013 |
| PCN108 CLINICAL EFFICACY AND ONCOLOGY REIMBURSEMENT RECOMMENDATIONS IN CANADA BY THE INTERIM JOINT ONCOLOGY DRUG REVIEW (IJODR) CC Ciapanna, D Shum, D Milliken, S Yunger Value in Health 14 (3), A174, 2011 | | 2011 |
| Cost-minimization analysis (CMA) of capecitabine plus oxaliplatin (XELOX) compared with modified FOLFOX6 (mFOLFOX6) for the adjuvant treatment of resected colon cancer in … S Yunger, B Mistry, WY Cheung, D Ksienski, A Urspruch Journal of Clinical Oncology 29 (15_suppl), e16538-e16538, 2011 | | 2011 |
| Timeliness of private access to intravenous (IV) cancer drugs: A Canadian analysis. P Douglas, S Yunger, JA Maroun, J Zabransky, M Byrne, M Ruzic, L Blair, ... Journal of Clinical Oncology 28 (15_suppl), e16533-e16533, 2010 | | 2010 |
| Canadian employers' awareness of and willingness to include intravenous cancer medicines on employee benefit private insurance plans. L Blair, S Yunger, T Benn, SR Sehdev, D Shum, D Milliken Journal of Clinical Oncology 28 (15_suppl), e16526-e16526, 2010 | | 2010 |
| Patient out-of-pocket and insurer payment decisions for bevacizumab for metastatic colorectal cancer: A Canadian analysis S Yunger, P Douglas, P Anglin, M Crump, S Lepage, D Shum, L Phillips, ... Journal of Clinical Oncology 27 (15_suppl), 6576-6576, 2009 | | 2009 |
George A. WellsUniversity of Ottawa確認したメール アドレス: ottawaheart.ca
